Edition:
United States

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

125.80USD
4:00pm EDT
Change (% chg)

$0.32 (+0.26%)
Prev Close
$125.48
Open
$125.37
Day's High
$126.14
Day's Low
$125.16
Volume
1,933,651
Avg. Vol
2,377,518
52-wk High
$129.00
52-wk Low
$107.70

Latest Key Developments (Source: Significant Developments)

Actelion says drug discovery business to be called Idorsia
Wednesday, 15 Mar 2017 02:40am EDT 

Actelion Ltd :Says drug discovery and early clinical pipeline business will be separated into a newly-created entity called idorsia ltd -- agm invitation.  Full Article

Actelion says granted marketing authorization by European Commission for Ledaga
Tuesday, 7 Mar 2017 01:00am EST 

Actelion Ltd :Actelion is granted marketing authorization by the European Commission for Ledaga (chlormethine gel) for the treatment of MF-CTCL.  Full Article

Janssen provides Nuevolution with further technology access fee payment
Monday, 6 Mar 2017 02:30am EST 

Nuevolution AB (publ) : Nuevolution announces further technology access fee payment from its drug discovery collaboration with Janssen Biotech, Inc. (Janssen) . Janssen, one of pharmaceutical companies of Johnson & Johnson , has used its option to expand collaboration with Nuevolution .Janssen has provided Nuevolution with technology access fee payment of $0.6 million (5.45 million Swedish crowns).  Full Article

Johnson & Johnson says received a subpoena in Feb. from the U.S. attorney's office for the District of Massachusetts
Monday, 27 Feb 2017 04:59pm EST 

J&J : j&j - in february 2017, johnson & johnson received a subpoena from the united states attorney's office for the district of massachusetts . j&j-feb 2017 subpoena seeks records related to payments to any 501(c)(3) charitable organization that provides financial assistance to medicare patients . Says it plans to file a new shelf registration on feb 27, which will enable it to issue debt securities on a timely basis . J&J - anticipates operating cash flows, existing credit facilities, access to capital markets will provide sufficient resources to fund operating needs in 2017 . J&J-in connection with medical devices unit restructuring, to record pre-tax restructuring related charges of about $2.0 billion to $2.4 billion - sec filing . J&J - about one-half of cumulative pre-tax costs from restructuring to result in cash outlays, including about $500 million of employee severance . J&J - in jan 2017, janssen pharmaceuticals, inc. Received a civil investigative demand (cid) from the united states department of justice (doj) .J&J - subpoena to janssen pharmaceuticals relates to allegations concerning the "sales and marketing practices" of olysio.  Full Article

Ethicon announces agreement to acquire Torax Medical
Friday, 17 Feb 2017 10:00am EST 

Ethicon Inc : Ethicon announces agreement to acquire Torax Medical, Inc. .financial terms of transaction have not been disclosed.  Full Article

Swiss Takeover Commission OKs J&J offer for Actelion
Thursday, 16 Feb 2017 03:01am EST 

Actelion Ltd :Swiss Takeover Commission says J&J offer for Actelion meets legal requirements.  Full Article

Renova Therapeutics enters into agreement to receive Stresscopin investigational new drug file from Janssen
Monday, 6 Feb 2017 11:00am EST 

Renova Therapeutics : Enters into agreement to receive Stresscopin investigational new drug file from Janssen . Renova holds an exclusive license to Stresscopin Peptide from nonprofit research development foundation .Plans to advance development of Stresscopin program as RT-400,peptide infusion treatment for episodes of acute decompensated heart failure.  Full Article

BRIEF-J&J says upon termination of transaction agreement, under some circumstances, Actelion may be obligated to pay co a fee
Wednesday, 1 Feb 2017 04:05pm EST 

Corrects source to Johnson & Johnson from Actelion Ltd.Johnson & Johnson :J&J - upon termination of transaction agreement, under some circumstances, Actelion may be obligated to pay co a fee - sec filing.  Full Article

ChemDiv announces multi-year hit identification collaboration with Janssen
Tuesday, 31 Jan 2017 09:00am EST 

Johnson & Johnson - : ChemDiv-Entered into hit identification collaboration with Janssen to identify potent hit series for range of targets across multiple therapeutic areas .ChemDiv- Janssen is granted open-ended access to Chemdiv's discovery chemistry platform.  Full Article

Fitch affirms Johnson & Johnson's IDR at 'AAA'; outlook stable
Friday, 27 Jan 2017 03:42pm EST 

Fitch:Fitch affirms Johnson & Johnson's IDR at 'AAA'; outlook stable.  Full Article

More From Around the Web

Photo

J&J, JPMorgan suspend YouTube ads over offensive videos

U.S. healthcare conglomerate Johnson & Johnson and JPMorgan Chase & Co became the latest big U.S. companies to suspend all digital advertising on Google's YouTube, over concerns that its ads may have appeared on channels that broadcast offensive videos. | Video